re: distribution happening; ripped HVAD
With a volume of only 45cc, the HVAD is believed to be the smallest full output long term circulatory assist device under development. HeartWare believes the HVAD to be the only device of its type that can be implanted in the space directly surrounding the heart, rather than in the abdomen. This leads to significant potential advantages, particularly in terms of the ease of surgical implantation and consequent patient benefits.
HeartWare believes that HVAD, once approved, will potentially offer patients and their treating physicians important benefits. These include the following:
A shorter, less traumatic surgical implantation procedure leading to:
faster recovery and hospital discharge
less severe post operative complications
Improved quality of life resulting from:
reduced levels of anticoagulation medication
reduced risk of stroke
improved reliability and durability of the device
- Forums
- ASX - By Stock
- HTW
- distribution happening
HTW
heartware limited
distribution happening, page-7
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HTW (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online